TITLE

Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion

AUTHOR(S)
Hollingsworth, Catherine
PUB. DATE
April 2008
SOURCE
BioWorld International;4/23/2008, Vol. 13 Issue 17, p6
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses the suspension of the Phase II trial study of the ACC-011 compound for Alzheimer's disease in 2008. The compound is being developed by Elan Corp. plc and Wyeth Pharmaceuticals. An announcement regarding the suspension was posted on April 17 on the Web site, www.clinicaltrials.gov.
ACCESSION #
31780094

 

Related Articles

  • Elan and Wyeth to take Alzheimer's drug to phase III.  // PharmaWatch: CNS;Jul2007, Vol. 6 Issue 7, p6 

    The article reports on the plan of Elan Corp. and Wyeth Pharmaceuticals to initiate a phase III clinical program for bapineuzumab, a humanized monoclonal antibody which is used to treat patients with mild to moderate Alzheimer's disease. According to the author, the move was based on a scheduled...

  • Elan/Wyeth unveil significant findings from phase IIa trial of AN-1792.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p7 

    Reports on the findings of Elan Corp. and Wyeth Pharmaceuticals Inc.'s phase IIa clinical trial of an investigational Alzheimer's disease treatment drug, AN-1792. Beta amyloid immunotherapy approach; Use of an immunologic approach to clear beta amyloid from the brain; Evidence of beta amyloid...

  • Elan and Wyeth start Phase III Alzheimer's trial for bapineuzumab.  // PharmaWatch: Biotechnology;Feb2008, Vol. 7 Issue 2, p6 

    The article reports on the Phase III clinical program for bapineuzumab in patients with mild to moderate Alzheimer's disease initiated by Elan Corp. PLC and Wyeth Pharmaceuticals in the U.S. The trial is intended to provide safety and efficacy data to support the filing and approval. It includes...

  • Elan-Wyeth Alzheimer's Trial Suspended Due to Skin Lesion. Hollingsworth, Catherine // BioWorld Today;4/21/2008, Vol. 19 Issue 77, p1 

    The article reports on the suspension of a Phase II trial of the ACC-011 compound for Alzheimer's diseases being developed by Elan Corp. PLC and Wyeth Pharmaceuticals in the U.S. According to the article, the trial has been suspended due to a skin lesion observed in a single patient. Wyeth...

  • Elan-Wyeth Alzheimer Trial Suspended.  // Bioworld Week;4/28/2008, Vol. 16 Issue 17, p2 

    The article reports on the suspension of Phase II trial of ACC-011 compound for Alzheimer's disease due to a skin lesion seen in a single patient. It states that the compound was developed by Elan Corp. Plc and Wyeth Pharmaceuticals, and both companies are sorting out the origin and cause of...

  • New Alzheimer's Routes In Targeting Of Amyloid, Tau.  // Bioworld Week;5/28/2007, Vol. 15 Issue 22, p1 

    The article reports development on bapineuzumab (AAB-001), which is a drug for mild to moderate Alzheimer's disease (AD). The report says that Elan Corp. PLC and Wyeth Pharmaceuticals has announced that the phase III testing for the drug would start later of 2007. It was reported that...

  • Call for Elan to publish Alzheimer's trial details. Bishop, Glenda M.; Robinson, Stephen R.; Smith, Mark A.; Perry, George; Atwood, Craig S. // Nature;4/18/2002, Vol. 416 Issue 6882, p677 

    Focuses on the request of the authors to Elan Pharmaceuticals to publish the details of the trial of the treatment of Alzheimer's disease. Release of Elan of details of their medical condition; Withdrawal of Elan of AN-1792 vaccine from human trials; Lack of obligation of Elan to report the...

  • Alzheimer's Drug Boosts Elan's Stock.  // Bioworld Week;5/28/2007, Vol. 15 Issue 22, p2 

    The article reports that the plan of Elan Corp. PLC and Wyeth Pharmaceuticals to begin Phase III testing of their immunotherapeutic candidate bapineuzumab for mild to moderate Alzheimer's disease in the second half of 2007 has boosted trading values of Elan's stocks. The reports says that Elan's...

  • J&J Deal Lifts Overhang on Elan Stock; Investors Cautious. Sheridan, Cormac // BioWorld International;7/8/2009, Vol. 14 Issue 27, p1 

    The article reports on the U.S.$1.5 billion partnership deal signed by Elan Corp. PLC with Johnson & Johnson covering its Alzheimer's disease immunotherapy program. The growth of Elan's drug was hampered by reports of progressive multifocal leukoencephalopathy (PML) occuring in multiple...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics